NCT05638451招募中2 期
Phase 2 Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年5月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Progression free survival rate at 6 months
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
详细描述
This is a phase 2,open-label, multicenter, single-arm study designed to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
A total of 30 patients will be enrolled in the study and administered Sintilimab in combination with Bevacizumab and Temozolomide. The study treatment will be continued for up to 4 cycles and Sintilimab was maintained until a progression of disease or unacceptable toxicity is confirmed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Molecular pathological diagnosis was high-grade glioma (2016 World Health Organization (WHO） Grade Ⅲ or Ⅳ);
- •Age 18 - 70 years old, Karnofsky performance status （KPS） score ≥ 70, and the expected survival period is more than 3 months;
- •Primary supratentorial glioblastoma with first or second recurrence
- •Imaging confirmed recurrence (according to RANO criteria);
- •The time of the first medication after enrollment should be more than 4 weeks away from the surgery or the last radiotherapy;
- •Confirmed progression time is ≥4 weeks from the last drug treatment (including adjuvant temozolomide chemotherapy after the completion of concurrent chemoradiotherapy);
- •If the patient is on hormone therapy, the hormone dose must be stable or reduced for at least 7 days before the baseline MRI examination;
- •Major organ function within 7 days prior to treatment, meeting the following criteria:
- •(1) Routine blood test standards (without blood transfusion within 14 days):
- •Hemoglobin (HB) ≥90 g/L;
- •Absolute neutrophil count (ANC) ≥ 1.5×10^9/L;
- •Platelet (PLT) ≥ 90×10^9/L; (2) Biochemical examination shall meet the following standards:
- •Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
- •Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5 ULN, if with liver metastasis, ALT and AST ≤ 5ULN;
- •Serum creatinine (Cr) ≤1.5 ULN and creatinine clearance rate (CCr) ≥ 60 ml/min; (3) Echocardiography: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%); (4) International normalized ratio (INR), partial thromboplastin time (APTT), prothrombin time (PT) ≤1.5 ULN;
- •Patients voluntarily joined the study and signed informed consent.
排除标准
- •Prior treatment with immunotherapy;
- •Patients who have had or are currently suffering from other malignant tumors or solid organ or bone marrow transplantation within 5 years. Excludes cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors;
- •Baseline MRI indicates the risk of cerebral hemorrhage or hernia in the past or recent;
- •Pulmonary embolism or deep vein thrombosis within 2 months
- •Unstable angina pectoris, myocardial infarction within past 12 months. Grade 2 or greater congestive heart failure
- •Peptic ulcer, abdominal fistula, gastrointestinal perforation, or abdominal abscess within past 6 months
- •Patients with any physical signs or history of bleeding, regardless of severity;
- •Uncontrollable high blood pressure
- •Patients with liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis;
- •Renal failure requires hemodialysis or peritoneal dialysis;
- •Known history of active infectious pneumonia and active tuberculosis.
- •Requiring escalating or chronic supraphysiologic doses of corticosteroids (> 4 mg dexamethasone daily) for control of disease
- •Allergic reaction to bevacizumab or any of its excipients
- •Diagnosis of immunodeficiency, including human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
- •Active autoimmune disease requiring systemic treatment (i.e., disease modifiers, corticosteroids, or immunosuppressive drugs) within past 2 years. Replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency, etc.) is not considered a systemic form of therapy.
- •Pregnancy or breastfeeding, or pregnancy or birth during the expected test period, from the pre-screening or screening visit until 120 days after the last dose of test treatment.
- •Unable to undergo brain MRI (i.e., pacemaker or any other MRI contraindications).
- •According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.
研究组 & 干预措施
Sintilimab and Bevacizumab and Temozolomide
Experimental
single arm study
干预措施: Sintilimab plus Bevacizumab and Temozolomide (Drug)
结局指标
主要结局
Progression free survival rate at 6 months
时间窗: Up to two years
Progression free survival by iRANO criteria
次要结局
- Overall survival(Up to two years)
- Objective response rate(Up to two years)
- Disease control rate(Up to two years)
- Progression free survival(Up to two years)
- Median duration of stable/improved quality of life assessed by EORTC QLQ-C30(Up to two years)
- Median duration of Karnofsky Performance Status(KPS) ≥ 70(Up to two years)
- Absolute counts and ratios of immune cell subtypes(Day 1 and Day 29 of each cycle)
- Frequency and severity of treatment-related adverse events(Up to two years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCEsophageal Squamous Cell CarcinomaNCT04514835The First Affiliated Hospital of Zhengzhou University44
Unknown
2 期
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerBrain MetastasesNon Small Cell Lung CancerSintilimabBevacizumabNCT04213170Sun Yat-sen University60
招募中
2 期
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLPrimary Mediastinal Diffuse Large B-cell LymphomaNCT06742502Sun Yat-sen University30
已完成
1 期
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT04072679Chinese Academy of Medical Sciences50
招募中
2 期
Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerIntrahepatic CholangiocarcinomaNCT05010681Fudan University25